BMO Capital Initiates Coverage On Novartis with Market Perform Rating, Announces Price Target of $114
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has initiated coverage on Novartis (NVS) with a Market Perform rating and set a price target of $114.

February 23, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BMO Capital initiated coverage on Novartis with a Market Perform rating and a price target of $114.
The initiation of coverage by BMO Capital with a Market Perform rating and a specific price target provides investors with a new analytical perspective on Novartis. However, the 'Market Perform' rating suggests that BMO Capital views NVS as likely to perform in line with the market, which does not necessarily indicate a strong positive or negative short-term price movement. The price target of $114 offers a benchmark for expectations but does not imply significant short-term volatility.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100